Blueprint Medicines Corporation (BPMC) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist Kathryn Haviland.
BPMC hat IPO-Datum 2015-04-30, 682 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $8.36B.
Blueprint Medicines Corporation is a precision therapy company that develops targeted medicines for genomically defined cancers and blood disorders globally. The company's marketed and pipeline products include AYVAKIT and BLU-263 for systemic mastocytosis and mast cell disorders, GAVRETO for RET fusion-positive cancers, Fisogatinib for hepatocellular carcinoma, and several investigational therapies targeting EGFR mutations in non-small-cell lung cancer, as well as rare genetic disorders. Blueprint maintains strategic collaborations with leading pharmaceutical partners including Genentech, Roche, CStone Pharmaceuticals, and Zai Lab to advance its precision medicine pipeline. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company is committed to delivering transformative treatments for patients with serious diseases driven by specific genetic alterations.
